(:MGTA)

Aug 07, 2023 04:03 pm ET
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Magenta Therapeutics, Inc. (NasdaqGM: MGTA) with Dianthus Therapeutics, Inc. pursuant to which Magenta shareholders are expected to own approximately 21.3% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
May 18, 2023 04:15 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, CHRA, STSA
NEW YORK, May 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
May 17, 2023 05:28 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MGTA, STSA, ROCC, CVT
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
May 13, 2023 08:18 pm ET
Lifshitz Law PLLC Announces Investigations of RUTH, MGTA, MDWT, and ISEE
Ruths Hospitality Group, Inc. (NASDAQ: RUTH) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of RUTH to Darden Restaurants, Inc. for $21.50 per share in cash....
May 11, 2023 09:54 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cvent Holding Corp. (Nasdaq - CVT), Absolute Software Corporation (Nasdaq – ABST), Home Point Capital, Inc. (Na
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
May 10, 2023 11:49 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, RUTH, HSKA
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Magenta Therapeutics, Inc. (NASDAQ:...
May 10, 2023 10:55 am ET
Moore Kuehn Encourages MGTA, HSKA, RUTH and SYNH Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
May 04, 2023 02:32 pm ET
Moore Kuehn Encourages RUTH, MGTA, MDWT, and CBOF Investors to Contact Law Firm
NEW YORK, May 4, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies.
May 04, 2023 12:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RUTH, MGTA, OPCH, AMED
NEW YORK, May 4, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
May 03, 2023 11:24 pm ET
Shareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with Dianthus
MILWAUKEE, May 3, 2023 /PRNewswire/ -- Ademi LLP is investigating Magenta (Nasdaq: MGTA) for possible breaches of fiduciary duty and other violations of law in its transaction with Dianthus. 
May 03, 2023 09:41 pm ET
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Magenta Therapeutics, Inc. (NasdaqGM: MGTA) with Dianthus Therapeutics, Inc. pursuant to which Magenta shareholders are expected to own approximately 21.3% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
May 03, 2023 11:37 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prom
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
May 03, 2023 08:33 am ET
MGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Magenta Therapeutics, Inc. (NASDAQ: MGTA) and Dianthus Therapeutics, Inc. is fair to Magenta shareholders. Upon completion of the proposed transaction, Magenta shareholders are expected to own approximately 21.3% of the combined company.
May 03, 2023 07:00 am ET
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) and Dianthus Therapeutics, Inc. (“Dianthus”), a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced...
Mar 31, 2023 04:10 pm ET
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan will give the...
Feb 03, 2023 10:01 am ET
Thinking about buying stock in Genetic Technologies, Heart Test Laboratories, Magenta Therapeutics, Carvana, or C3.ai?
NEW YORK, Feb. 3, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GENE, HSCS, MGTA, CVNA, and AI.
Feb 02, 2023 04:05 pm ET
Magenta Therapeutics to Explore Strategic Alternatives
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company focused on improving stem cell transplantation, today announced that it has completed a review of its business, including the status of its programs, resources, and...
Jan 25, 2023 04:05 pm ET
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and...
Dec 20, 2022 09:00 am ET
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
Magenta Therapeutics (Nasdaq: MGTA) today announces that, per the clinical trial protocol for the MGTA-117 Phase 1/2 Dose Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), it has...
Dec 13, 2022 07:41 am ET
Thinking about buying stock in Magenta Therapeutics, Ventyx Biosciences, Wave Life Sciences, Oncternal Therapeutics, or EHang Holdings?
NEW YORK, Dec. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGTA, VTYX, WVE, ONCT, and EH.
Dec 12, 2022 04:30 pm ET
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, highlights updated clinical data from the ongoing MGTA-117 Phase...
Dec 12, 2022 08:00 am ET
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at...
Nov 03, 2022 09:01 am ET
Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today reported financial results for the third quarter ending...
Nov 03, 2022 09:01 am ET
Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will make three presentations relating to...
Nov 01, 2022 08:00 am ET
Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will present at the Credit Suisse...
Aug 17, 2022 08:00 am ET
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Michael Vasconcelles, M.D....
Aug 04, 2022 08:00 am ET
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today reported financial results for the second quarter ending...
Aug 02, 2022 08:00 am ET
Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will participate in a Gene...
May 16, 2022 08:00 am ET
Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today reported financial results for the first quarter ending March 31, 2022, early clinical observations from its MGTA-117 clinical trial and other recent program highlights.
Apr 14, 2022 08:00 am ET
Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced progress and encouraging early data in its MGTA-117 Phase 1/2 targeted conditioning clinical trial and a prioritization of its operating plan to more narrowly focus its capital allocation on the MGTA-117 targeted conditioning program, the CD45-ADC (antibody-drug conjugate) IND-enabling activities and the MGTA-145 stem cell mobilization efforts in sickle cell disease.
Mar 08, 2022 08:00 am ET
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today reported financial results for the fourth quarter and full-year ended December 31, 2021, and recent program highlights.
Mar 03, 2022 08:00 am ET
Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in a Cell Therapy Panel Discussion at the 42nd Annual Cowen Healthcare Conference, to be held virtually, on Wednesday, March 9th, 2022 at 9:10 a.m. ET.
Jan 18, 2022 07:00 am ET
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a multinational biopharmaceutical and diagnostics company, today announced they have signed a definitive...
Jan 10, 2022 08:00 am ET
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today highlighted progress across its portfolio of targeted conditioning and stem cell mobilization programs and set out its milestone expectations for both clinical and preclinical data in 2022. These updates will also be discussed during a webcast presentation at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 9:45 a.m. EST.
Jan 05, 2022 08:00 am ET
Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following January investor conferences:
Dec 14, 2021 09:00 am ET
Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today highlighted three presentations made at the 2021 American Society of Hematology (ASH) Annual Meeting.
Nov 04, 2021 09:10 am ET
Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today reported financial results for the third quarter ended September 30, 2021, and recent program highlights.
Nov 04, 2021 09:09 am ET
Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced positive top-line results from an investigator-initiated Phase 2 clinical trial of MGTA-145 stem cell mobilization in multiple myeloma. The
Oct 04, 2021 08:00 am ET
Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced the appointment of Jeffrey Humphrey, M.D., as the company’s Chief Medical Officer where he will be responsible for all clinical
Sep 21, 2021 08:00 am ET
Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference
Magenta Therapeutics, Inc. (Nasdaq:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28 at 4:40 p.m. ET.
Sep 15, 2021 08:00 am ET
Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced today that its Investigational New Drug (IND) application for MGTA-117 is active with the U.S. Food and Drug Administration (FDA). The company expects to open the Phase 1/2 clinical trial in Q4 2021 to evaluate its MGTA-117 antibody-drug conjugate (ADC) targeted conditioning program.
Aug 05, 2021 08:00 am ET
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the second quarter ended June 30, 2021, and recent program highlights.
Aug 03, 2021 05:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Aug 03, 2021 08:00 am ET
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:
Jul 28, 2021 07:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Jul 26, 2021 08:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Jul 21, 2021 10:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
NEW YORK, July 21, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 21, 2021 08:00 am ET
Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
Magenta Therapeutics, Inc. (Nasdaq: MGTA) today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) filed in June 2021 to initiate a Phase 1/2 clinical trial of MGTA-117 in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Jul 06, 2021 08:00 am ET
Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company’s first Chief Commercial Officer.
Jun 14, 2021 08:00 am ET
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Thomas Beetham as Chief Legal Officer.
Jun 04, 2021 09:00 am ET
Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clini
“We are very pleased to see continued favorable results for MGTA-145 and plerixafor for stem cell mobilization and collection in patients with multiple myeloma,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. “These results build on those previously disclosed from this study and the Phase 1 trials to further demonstrate MGTA-145 and plerixafor’s potential as a rapid, reliable, well-tolerated approach to stem cell mobilization and collection, which has positive implications for patients and donors.”
Jun 03, 2021 08:00 am ET
Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 4:40 p.m. ET.
May 14, 2021 08:00 am ET
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, will participate in fireside chats at the following investor conferences this month:
May 12, 2021 10:00 am ET
Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has agreed to sell approximately 9,600,000 shares of its common stock to certain institutional investors in a private placement. Magenta anticipates aggregate gross proceeds from the offering will be $86.4 million, before deducting estimated offering expenses payable by the Company, based on the offering price of $9.00 per share. The financing syndicate includes Deep Track Capital, L.P., TCG X, Great
May 12, 2021 10:00 am ET
Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced positive preliminary results from its Phase 2 clinical trial of MGTA-145 plus plerixafor in patients with multiple myeloma, which were accepted for presentation at the European Hematology Association (EHA) Congress, to be held virtually June 9-17, 2021. Magenta also provided initial direction regarding the acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients it expects to
May 06, 2021 08:00 am ET
Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the first quarter ended March 31, 2021 and recent program highlights.
Apr 19, 2021 08:00 am ET
Magenta Therapeutics Appoints David Nichols as Chief Technical Officer
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of David Nichols as Chief Technical Officer.
Mar 25, 2021 08:00 am ET
Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, is scheduled to participate in a panel discussion at
Mar 15, 2021 08:00 am ET
Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marr
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced availability of data presentations across its stem cell mobilization and targeted conditioning programs at the European Society for Blood and Marrow Transplantation (EBMT) 2021 annual meeting, held virtually March 14-17, 2021.
Mar 09, 2021 08:00 am ET
Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to present at the Oppenheimer 31st Annual Healthcare Conference, to be held virtually, on Thursday, March 18
Mar 03, 2021 08:00 am ET
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the fourth quarter and full-year ended December 31, 2020 and recent program highlights.
Feb 08, 2021 08:00 am ET
Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at Transplantation and Cellular Therapy (
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today announced data presentations across its stem cell mobilization and targeted conditioning programs at the Transplantation and Cellular Therapy (TCT) Annual Meeting, to be held virtually on February 8-12, 2021.
Jan 11, 2021 08:00 am ET
Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today highlighted progress across its stem cell mobilization and collection and targeted conditioning programs, and set expectations for 2021. These updates will be discussed during a webcast presentation at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 7:50 a.m. PST / 10:50 a.m. EST.
Jan 05, 2021 08:00 am ET
Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually, on Thursday, January 14th
Dec 07, 2020 08:00 am ET
Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditionin
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced final clinical results from its earlier completed Phase 1 clinical trial as well as development updates for its MGTA-145 stem cell mobilization therap
Dec 04, 2020 08:00 am ET
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell
Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). The data from this clinical trial could p
Nov 09, 2020 08:00 am ET
Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of Steve Mahoney as Chief Financial and Operating Officer.
Nov 05, 2020 08:00 am ET
Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business highlights and financial results for the third quarter ended September 30, 2020.
Nov 04, 2020 11:02 am ET
Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the American Society of Hematology (ASH) annual meeting, to be held D
Sep 11, 2020 08:00 am ET
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following September investor conferences:
Sep 02, 2020 12:00 pm ET
Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced it is part of a multi-project, broad-based research effort awarded a five-year, $14.6 million U19 grant from the National Institutes of Health (NIH) to explor
Sep 02, 2020 08:00 am ET
Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operati
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as Senior Vice President, Head of Regula
Aug 31, 2020 08:00 am ET
Magenta Therapeutics Announced It Will Present Clinical and Pre-Clinical Data from Across Immune and Blood System Reset Portfolio at European Society for Blood and Marrow Transplantation (EBMT) Annual
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data across the portfolio will be presented at the European Society for Blood and Marrow Transplantation (EBMT) annual meeting, held August 29 to
Aug 06, 2020 08:00 am ET
Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported recent business highlights and financial results for the second quarter ended June 30, 2020.
Aug 03, 2020 04:05 pm ET
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following August investor conferences:
Jul 15, 2020 07:58 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 7980. The investigation...
Jun 30, 2020 08:00 am ET
Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing of its previously announced underwritten public offering of 8,625,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,125,000 shares, at a price to the public of $8.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected
Jun 24, 2020 08:20 pm ET
Magenta Therapeutics Announces Pricing of Public Offering
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.00 per share. Magenta also granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $60.0 m
Jun 24, 2020 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
NEW YORK, June 24, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 24, 2020 05:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
NEW YORK, June 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 24, 2020 04:21 pm ET
Magenta Therapeutics Launches Proposed Public Offering
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of $60 million of its common stock. Magenta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Magenta.
Jun 22, 2020 06:54 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Jun 16, 2020 03:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Jun 15, 2020 11:00 am ET
MGTA Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Magenta Therapeutics, Inc. and Encourages Investors to Contact the Firm
NEW YORK, June 15, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Investors who purchased Magenta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mgta.                        
Jun 15, 2020 06:00 am ET
Jun 11, 2020 03:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Pomerantz LLP is investigating claims on behalf of investors of  Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Jun 11, 2020 07:30 am ET
Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today provided a portfolio update, highlighting progress and recent updates across its most advanced programs.
Jun 08, 2020 04:30 pm ET
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in a fireside chat and hold investor meetings at the 41st annual Goldman Sachs Healthcare Conference on June 11
Jun 05, 2020 08:30 am ET
Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported the presentation of preclinical data showing successful immune reset with a single dose of its CD45-ADC in models of three autoimmune diseases. Magenta also highlighted data from its Phase 1 study of first-line stem cell mobilization therapy MGTA-145. These results were presented this week at the European League Against Rheumatism (EULAR) annual meeting.
May 14, 2020 08:00 am ET
Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of blood and immune reset to more patients, presented preclinical data on its stem cell mobilization therapy clinical candidate, MGTA-145, this week at the annual meeting of the American Society of Gene and C
May 07, 2020 07:30 am ET
Magenta Therapeutics Reports Recent Business Highlights and First Quarter Financial Results
“The first quarter of 2020 has shown Magenta to be well-positioned to advance our programs and to weather unexpected obstacles. Magenta continues to execute and progress our pipeline, and we remain committed wholeheartedly to our patients, their families, our employees and our business partners,” said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta. “In this first quarter, Magenta has showcased significant clinical and preclinical results, and we are building on these results to advance quickly.”
May 06, 2020 07:00 am ET
May 06, 2020 07:00 am ET
Apr 30, 2020 08:00 am ET
Magenta Therapeutics to Host Business Update Conference Call
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced it will host a conference call on Thursday, May 7, 2020 at 8:00am ET to discuss recent business updates. The call will also feature a discussion of current ste
Apr 28, 2020 04:30 pm ET
Magenta Therapeutics to Present Data from Across Portfolio at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that data from across its portfolio will be presented at the ASGCT annual meeting, to be held May 12-15, 2020.
Apr 17, 2020 08:11 am ET
Magenta Therapeutics Names John Davis Jr., M.D., M.P.H, M.S., Head of Research and Development
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that it has promoted John Davis Jr., M.D., M.P.H., M.S. to Head of Research and Development and Chief Medical Officer.
Apr 16, 2020 08:00 am ET
Magenta Therapeutics Provides Business Update
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today provided a current update on its programs, business and operations.
Mar 03, 2020 08:00 am ET
Magenta Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today reported financial results for the fourth quarter and full year ended December 31, 2019 and recent business highlights.
Feb 26, 2020 08:30 am ET
Magenta Therapeutics to Participate in Cowen Health Care Conference on Monday, March 2nd in Boston
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to participate in a fireside chat at the 40th annual Cowen Health Care Conference on Monday, March 2nd, 2020, at 4:10
Feb 24, 2020 08:30 am ET
Magenta Conditioning Lead Clinical Candidate MGTA-117 Demonstrates Broad Tolerability and High Therapeutic Index in Non-human Primates
Magenta has created a new stem cell biology discovery platform to harness the curative power of immune reset through stem cell transplant for more patients, and is developing a comprehensive portfolio of novel therapeutics to allow more patients to benefit through a more precise stem cell transplant process. This portfolio includes targeted, disease-modifying antibody drug conjugates (ADCs), such as MGTA-117, that are designed to precisely and rapidly remove the disease-causing cells in the body and enable immune system reset and long-term engraftment without the need for chemotherapy or radia
Feb 24, 2020 08:30 am ET
Magenta Therapeutics Completes Dosing in Phase 1 MGTA-145 Trial, Demonstrating Rapid, Single-Day First Line Stem Cell Mobilization and Collection
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the completion of dosing in its Phase 1 trial of stem cell mobilization therapy clinical candidate, MGTA-145, as well as updated clinical data from the trial
Feb 20, 2020 08:30 am ET
Magenta Therapeutics Announces Updated Phase 2 Data on MGTA-456 Cell Therapy, Demonstrating Continued Durability in Inherited Metabolic Disorders
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced updated clinical data from Phase 2 trials of its cell therapy, MGTA-456, at the Transplant and Cellular Therapy (TCT) Annual Meeting in Orlando, Florida. New
Feb 06, 2020 08:30 am ET
Magenta Therapeutics to Participate in Guggenheim Healthcare Talks Oncology Day on Thursday, February 13th in New York City
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 13th, 2020, a
Feb 05, 2020 08:30 am ET
Magenta Therapeutics Expands Leadership Team, Appoints Kristen Stants as Chief People Officer and Li Malmberg as Senior Vice President, Head of Manufacturing
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the expansion of its senior leadership with two new strategic hires, Kristen Stants as Chief People Officer and Li Malmberg, Ph.D., as Senior Vice President,
Jan 13, 2020 08:00 am ET
Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today highlighted recent progress across several programs and outlined goals for 2020. These updates will be discussed during a webcast presentation at the 38th an
Jan 06, 2020 08:30 am ET
Magenta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th in San Francisco
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15th
Dec 09, 2019 07:45 am ET
Magenta Therapeutics Demonstrates First-ever Successful Gene Therapy Transplant Without Chemotherapy in Primates Using a Single Dose of Antibody-drug Conjugate
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its CD117-ADC patient preparation program were presented at the 61st Annual Meeting of the American Society of Hematology (AS
Dec 07, 2019 05:30 pm ET
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that new results from its MGTA-145 stem cell mobilization program were presented at the 61st Annual Meeting of the American Society of Hematology (
Nov 26, 2019 04:05 pm ET
Magenta Therapeutics to Present at the Evercore ISI HealthCONx Conference on Tuesday, December 3rd
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to participate in a fireside chat at the Evercore ISI HealthCONx Conference on December 3, 2019 at 1:15 p.m. ET at the F
Nov 13, 2019 08:00 am ET
Magenta Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the third quarter ended September 30, 2019 and recent business highlights.
Nov 11, 2019 08:30 am ET
Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACR
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported new data showing successful immune reset with a single dose of its CD45-ADC in models of three autoimmune diseases. These results were presented yesterday at the American College of Rheumatology (ACR) Annual Meeting in Atlanta, Ga.
Nov 06, 2019 09:00 am ET
Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that new data from across its pipeline will be presented at the 61st Annual Meeting of the American Society of Hematology (ASH).
Oct 16, 2019 08:30 am ET
Magenta Therapeutics Appoints Jan Pinkas as Senior Vice President, Head of Translational Sciences and Announces Transition of Chief Scientific Officer
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the appointment of Jan Pinkas, Ph.D., as Senior Vice President, Translational Sciences. The Company also announced that Mike Cooke, Ph.D., Chief Scientific Officer,
Sep 04, 2019 08:30 am ET
Magenta Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to MGTA-456 for the Treatment of Inherited Metabolic Disorders
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advance Therapy (RMAT) designation for MGTA-456, a one-time cell therapy for the treat
Aug 08, 2019 08:00 am ET
Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the second quarter ended June 30, 2019 and recent business highlights.
Aug 06, 2019 08:30 am ET
Magenta Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13th
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Wedbush PacGrow Healthcare Conference on August 13, 2019 at 3:05 p.m. ET at the Parker New York in New York City.
Jul 12, 2019 02:29 pm ET
CORRECTING and REPLACING Magenta Therapeutics Appoints Anne McGeorge to Board of Directors
Reissuing release dated June 24th, 2019 to correct for searching purposes.
Jun 06, 2019 04:05 pm ET
Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Goldman Sachs Global Healthcare Conference on June 11, 2019 at 2:40 p.m. PT/5:40
May 09, 2019 08:00 am ET
Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results for the first quarter ended March 31, 2019 and recent business highlights.
May 09, 2019 07:30 am ET
Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology Annual Meeting
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company presented Phase 2 clinical data on its cell therapy, MGTA-456, at the annual meeting of the American Academy of Neurol
May 06, 2019 04:05 pm ET
Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the closing of its previously announced public offering of 4,887,500 shares of its common stock, including 637,500 shares
May 01, 2019 08:11 pm ET
Magenta Therapeutics Announces Pricing of Public Offering
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the pricing of its public offering of 4,250,000 shares of its common stock at a price to the public of $13.25 per share,
Apr 29, 2019 04:32 pm ET
Magenta Therapeutics Launches Proposed Public Offering
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock.
Apr 29, 2019 08:00 am ET
Magenta Therapeutics to Present Preclinical Data on E478 Stem Cell Gene Therapy Expansion Program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the Company will highlight preclinical data on its E478 program in an oral presentation on Thursday, May 2, at the annual meeting of the
Apr 24, 2019 08:30 am ET
Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has dosed the first subjects in a Phase 1 study of MGTA-145. Magenta intends to develop MGTA-145 in autoimmune diseases, blood
Mar 19, 2019 07:30 am ET
Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018.
Mar 06, 2019 04:05 pm ET
Magenta Therapeutics to Present at Investor Conferences in March
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the following investor conferences:
Feb 25, 2019 08:15 am ET
Magenta Therapeutics Presents Clinical and Preclinical Data on MGTA-456 Cell Therapy in Best Abstracts Sessions at Transplant and Cellular Therapy (TCT) Annual Meeting
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company presented Phase 2 clinical data and preclinical research on its MGTA-456 program at the TCT annual meeting.
Feb 25, 2019 08:15 am ET
Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company highlighted preclinical research on its targeted conditioning programs in four presentations and posters at the Transpl
Feb 21, 2019 08:00 am ET
Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented new preclinical research on its MGTA-145 product candidate for stem cell mobilization at the Transplant an
Feb 07, 2019 08:30 am ET
Magenta Therapeutics to Present at Guggenheim Healthcare Investor Conference
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company is scheduled to present at the Guggenheim Healthcare Talks Idea Forum Oncology Day on Thursday, February 14th
Jan 02, 2019 08:30 am ET
Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the company is scheduled to present and subsequently participate in a Q&A session at the 37th Annual J.P. Morgan Heal
Dec 02, 2018 09:00 pm ET
Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented initial Phase 2 clinical data and preclinical research on its MGTA-456 program at the 60th annual meeting o
Dec 02, 2018 09:00 pm ET
Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company presented preclinical research on its targeted conditioning programs at the 60th annual meeting of the American Socie
Dec 01, 2018 12:30 pm ET
Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company highlighted new preclinical research on its MGTA-145 product candidate for stem cell mobilization in an oral present
Nov 26, 2018 08:30 am ET
Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that it will host a live webcast of an investor and analyst event at 8:30 p.m. PST (11:30 p.m. EST) on Sunday, December 2, 2018, durin
Nov 19, 2018 08:00 am ET
Magenta Therapeutics Appoints Jason Ryan as Chief Operating and Financial Officer
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that it has strengthened its executive team with the appointment of Jason Ryan as Chief Operating and Financial Officer, effective Ja
Nov 08, 2018 08:00 am ET
Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today reported financial results and business highlights for the third quarter ended September 30, 2018.
Nov 01, 2018 09:00 am ET
Magenta Therapeutics Announces Acceptance of Nine Abstracts Covering Clinical and Preclinical Data at ASH, Representing Progress across the Portfolio of Conditioning, Stem Cell Mobilization and Expans
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company will present clinical data and preclinical research at the 60th annual meeting of the American Society of Hematology
Sep 24, 2018 08:30 am ET
Magenta Therapeutics Added to Russell 2000 and 3000 Indexes
Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the company has been added to the Russell 2000 and 3000 indexes following the Russell U.S. Indexes’ quarterly update.
Aug 09, 2018 04:05 pm ET
Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today reported financial results and business highlights for the second quarter ended June 30, 2018.
Aug 08, 2018 04:05 pm ET
Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced that the Company is scheduled to present at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14th, at 9:10
Jun 25, 2018 04:05 pm ET
Magenta Therapeutics Announces Closing of Initial Public Offering
Magenta Therapeutics, Inc. (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients, today announced the closing of its initial public offering of 6,666,667 shares of its common stock at a price to the public of $15.00 per share.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.